NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead...
Related Questions
What specific securities violations are alleged in this notice?
How many shareholders are likely to be part of the class and could this affect the size of potential liabilities?
What is the estimated financial exposure for Capricor Therapeutics if the case results in a settlement or judgment?
When is the deadline for filing claims and how might that deadline influence short‑term stock price movements?
Could this lawsuit impact the company’s cash reserves or its ability to raise additional capital?
What is the probability of a negative outcome for Capricor Therapeutics based on similar past biotech securities cases?
How might the announcement of this legal action affect trading volume and volatility in the near term?
Are there any comparable cases in the sector and what was their effect on the involved companies’ stock performance?
What are the potential long‑term implications for the company’s valuation and strategic plans if the case proceeds to litigation?
What steps, if any, is management taking to mitigate the impact of this lawsuit on shareholders and the market?